

PATENT Docket No. 286002021121

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on June 13, 2002.

Garce A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

JUN 2 5 2002

In the application of:

Chaitan KHOSLA and Blaine PFEIFER

Serial No.:

10/087,451

Filing Date:

February 28, 2002

For:

BIOSYNTHESIS OF POLYKETIDE

SYNTHASE SUBSTRATES

Examiner: To Be Assigned TECH CENTER 1600/2900

Group Art Unit: 1652

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. A copy of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Numbers 09/687,855, filed October 13, 2000; and 09/798,033, filed February 28, 2001, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application. The Examiner is requested to make these documents of record.

	This In	formation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
\boxtimes	Withi	n three months of the application filing date or before mailing of a first Office
	Actio	n on the merits; accordingly, no fee or separate requirements are required.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	n or Notice of Allowance.
		A fee is required. A check in the amount of * is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of * is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 286002021121. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June $\frac{3}{2}$, 2002

Respectfully submitted,

By:

Çarolyn A. Favorito Registration No. 39,183

Morrison & Foerster LLP 3811 Valley Centre Drive Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5195 Facsimile: (858) 720-5125

Form PTO-1449				Docket Number 286002021121 Applic		Application Nu	lication Number 10/087,451			
INFORMATION DISCLOSURE CITATION				Applicant						
IN ANOTHE SATION				Chaitan KHOSLA and Blaine PFEIFER 👤 👤						
				Filing Date: February 28, 2002 Group Ar			CENTER 1600, 2900	JUN (
	(3	JUN 1 9 2002	? 👊		Mailing Date: June 13,	2002		TER	2.5	
	(2007						160	2002	
		PADEMARY	·/					0 22	22 J	
			U.S. PA	TEN.	Г DOCUMENTS			90	(
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	Filing Da Appropr		
			FOREIGN I	PATE	ENT DOCUMEN	TS				
Examiner Initials	Ref. No.	Date	Document No.		Country	Class	Subclass	Translat YES	tion NO	
	1.	03/30/95	WO 9508548	WO						
	2.	06/25/98	WO 9827203	WO						
	3.	04/22/99	WO 9919518	wo						
	4.	01/28/99	WO 9903986	WO						
	5.	04/13/00	WO 0020601	WO	1					
			ОТНЕ	R DO	OCUMENTS	(includi	ng author, title, Da	te, Pertinent Pag	ges, Etc.)	
Examiner Initials	Ref. No.	Title								
	6.	An et al. (1998). Eur. J. Biochem. 257:395-402								
	7.	Anderson, M.G. et al. (1989). J Chem Soc Chem Commun 311-313								
	8.	August, P.R. et al. (1998). Chem Biol 5:69-79.								
	9.	Cane, D.E. et al. (1998). Science 282:63.								
	10.	Donadio, S. et al. (1996). Molecular Microbiology 19(5):977-984.								
	11.	Du, L. et al. (2000). Chem Biol 7:623-640.								
	12.	Floss, H.G. et al. (1999). Curr Opin Chem Biol 3:592-597.								
	13.	Gehring, A.M. et al. (1998). Chem Biol 5:573-586.								
	14.	Ghisalba, O. et al. (1981). J Antibiot 34:64-71.								
	15.	Gokhale, R.S et al. (1999). Science 284:482-485.								
	16.	Hsieh, Y-J et al. (1994). Journal of Bacteriology 176(3):714-724.								
	17.	Hunziker, D	. et al. (1998). J Ame	r Che	m Soc 120:1092-10)93.				
EVALO	VICD:	***			DATE COM	IDEDED				
ЕХАМП	NEK:				DATE CONS	IDEKED:				
			idered, whether or not the				line through the	citation if not i	n	



Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

			- 0	
Docket Number 286002021121	Application Number 10	Application Number 10/087,451		
Applicant				
Chaitan KHOSI	A and Blaine PFEIFER			
Filing Date: February 28, 2002	Group Art Unit:1652	G.	,	
Mailing Date: June 13, 2002			S	
			2	
1.60		7	۲:	

18.	Julien, B. et al. (2000). Gene 249:153-160.
19.	Kao, C.M. et al. (1994). Science 265(5171):509-512.
20.	Khosla, C. et al. (1999). Annual Review of Biochemistry 68:219-253. Pfeifer B A at al. (2001). Microbiology and Molecular Biology Paviews 65(1):106-118
21.	Pfeifer, B.A. et al. (2001). Microbiology and Molecular Biology Reviews 65(1):106-118.
22.	Pfeifer, B.A. et al. (2001). Science 291(5509):1790-1792.
23.	Quadri, L.E. et al. (1998). Chem Biol5:631-645.
24.	Quadri, L.E. et al. (1998). Biochemistry 37(6):1585-1595.
25.	Rodriquez, E. et al. (1999). Microbiology 145:3109-3119.
26.	Silakowski, B. et al. (1999). J Biol Chem 274:37391-37399.
27.	Schupp, T. et al. (1998). FEMS Microbiol Lett 159:201-207.
28.	Schwecke, T. et al. (1995). Proc Natl Acad Sci USA 92:7839-7843.
29.	Spratt et al. (1981). J. Bacteriol. 146(3):1166-1169
30.	Stassi, D.L. et al. (1998). Proceedings of the National Academy of Sciences of USA 95(13):7305-7309.
31.	Tang, L. et al. (1994). Journal of Bacteriology 176(19):6107-6119.
32.	Tang, L. et al. (1998). Gene 216:255-265.
33.	Tilett, D. et al. (2000). Chem Biol 7:753-764.
34.	Umeyama, T. et al. (1996). FEMS Microbiology Letters 144(2-3):177-184.
35.	Wu, K. et al. (2000). Gene 251:81-90.
36.	Zhang, W. et al. (1999). Applied Biochemistry and Biotechnology 82(3):209-225.
37.	Ziermann, R. et al. (1999). Biotechniques 26(1):106-110.

EXAMINER: DATE CONSIDERED:

EXAMINER Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.